A comparative study of cefoselis and ceftazidime in bacterial pneumonia

Rinzo Soejima, Yoshihito Niki, Osamu Moriya, Masamitsu Nakajima, Kenjiro Kikuchi, Yoshinobu Osaki, Hitoshi Nakano, Jun Ichi Maruyama, Hideaki Omiya, Tetsuo Shimizu, Toshiaki Fujikane, Hirotaka Hashizume, Yuka Fujita, Tadakatsu Tsuji, Akira Saito, Kazuo Takebe, Mitsuo Masuda, Seiichi Murakami, Hisashi Nakahata, Kazuki KonishiHiroshi Inoue, Kenichi Takeuchi, Masashi Tamura, Toshihiro Nukiwa, Akira Watanabe, Yushi Nakai, Yoshihiro Honda, Shigeo Takizawa, Kenji Yanase, Mikae Nakamura, Kohya Shiba, Osamu Sakai, Kazuhisa Okada, Atsushi Saito, Mitsuo Sakamoto, Hiroichi Tanimoto, Tetsuo Okamura, Ayumu Shimizu, Taichi Mochizuki, Kaoru Shimada, Yasuyuki Sano, Yasuo Arai, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Fumio Matsumoto, Takeo Imai, Nahoko Shindo, Shoichiro Irimajiri, Yasuo Matsuoka, Yasuo Osone, Norio Kikuchi, Masaaki Arakawa, Kouichi Wada, Shigeyuki Hoshino, Akira Iwashima, Fumihide Iwata, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Atsuhiko Sato, Masatoshi Iwata, Rinko Kita, Masaaki Ida, Yutaka Nakano, Takayoshi Watanabe, Toshihiko Takeuchi, Yasuo Yamada, Atsushi Nakamura, Hidekazu Hanaki, Makoto Kawakami, Shinji Takeyamac, Ikuji Usami, Hideaki Kuroki, Fumio Miki, Eiro Tsubura, Tomio Masuno, Hitoaki Okamori, Kazuo Nishii, Masaru Nakagawa, Toshihiko Yamaguchi, Yoshihiro Takishita, Hiroyasu Bando, Yoshihiro Suzuki, Nobuhiro Narita, Keiichi Mikasa, Masayoshi Sawaki, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yuji Sugimoto, Ikuo Matsumoto, Masahiko Hiramoto, Kikuo Nakano, Jiro Takahara, Jiro Fujita, Yasufumi Yamaji, Masaru Kamei, Yoshiro Sawae

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    The clinical efficacy, safety and usefulness of cefoselis (FK 037, CFSL), a new parenteral cephalosporin, were evaluated in bacterial pneumonia in a comparative study with ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days. The following results were obtained. 1. Of the total 178 patients enrolled, 138 were evaluated for clinical efficacy and the efficacy rates ('good' and better responses) were 91.9% (68/74) in the CFSL group and 92.2% (59/64) in the CAZ group. 2. Bacteriological effects (eradication rates) were 100% (18/18) in the CFSL group and 96.0% (24/25) in the CAZ group. 3. Adverse reactions occurred in 3 of the 66 patients (3.5%) in the CFSL group and in 3 of the 84 patients (3.6%) in the CAZ group. The incidence of abnormal laboratory findings was 20.9% (18/86) in the CFSL group and 19.0% (15/79) in the CAZ group. The safety rate ('safe' in the overall safety rating) was 77.9% (67/86) in the CFSL group and 81.0% (64/79) in the CAZ group. 4. Usefulness rates ('useful' and better responses) were 89.2% (66/74) in the CFSL group and 87.5% (56/64) in the CAZ group. No significant difference was observed between the two groups in any of the above ratings. The results indicate that cefoselis is as useful as ceftazidime for the treatment of bacterial pneumonia. This paper reports clinical results excluding cases violating Good Clinical Practice (GCP) found after publication of our previous paper in 'Jpn. J. Chemother.' (Vol. 43, No. 4, 1995).

    Original languageEnglish
    Pages (from-to)509-526
    Number of pages18
    JournalJapanese Journal of Chemotherapy
    Volume44
    Issue number7
    Publication statusPublished - 1996

    Keywords

    • FK 037
    • cefoselis

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'A comparative study of cefoselis and ceftazidime in bacterial pneumonia'. Together they form a unique fingerprint.

    Cite this